Background: Osteosarcoma (OS), the most common pediatric bone tumor, faces challenges with frequent relapse despite treatment advances. Identifying early diagnostic biomarkers and therapeutic targets is critical. The purpose of this study was to investigate the novel biomarkers for OS, and we also aimed to explore whether these biomarkers could potentially serve as the therapy targets.
View Article and Find Full Text PDF